NCT04787263View on ClinicalTrials.gov

CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 4, 2021

Primary Completion Date

March 3, 2025

Study Completion Date

March 3, 2038

Conditions
Acute Lymphoblastic LeukemiaDiffuse Large B Cell LymphomaPrimary Mediastinal Lymphoma
Interventions
BIOLOGICAL

CD19-CAR_Lenti T cell

Fresh peripheral blood mononuclear cells are manufactured to obtain CD19-CAR\_Lenti T cell, second generation CAR T cells incorporating the 4-1BB costimulatory domain. The fresh product is infused following lymphodepletion chemotherapy at a dose of 1.0-3.0x10\^6 CAR+ cells/kg.

Trial Locations (1)

00165

RECRUITING

IRCCS Ospedale Pediatrico Bambino Gesù, Roma

All Listed Sponsors
lead

Bambino Gesù Hospital and Research Institute

OTHER